Evolus (EOLS) Earns “Buy” Rating from Cantor Fitzgerald
Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating restated by Cantor Fitzgerald in a research note issued on Monday. They currently have a $35.00 price target on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 86.12% from the company’s previous close.
The analysts wrote, “Based on our due diligence, dermatologists and plastic surgeons appreciate the value proposition of Evolus’s botulinum toxin as a nearly identical product to market-leader Botox sold at a discount. Therefore, we think DWP-450 could pick up meaningful market share if it is approved. and other potential upcoming catalysts should drive EOLS shares higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $35 12-month price target.””
Several other equities research analysts have also issued reports on EOLS. ValuEngine raised shares of Evolus from a “hold” rating to a “buy” rating in a report on Monday, July 2nd. JMP Securities upped their target price on shares of Evolus from $22.00 to $30.00 and gave the stock an “outperform” rating in a report on Tuesday, May 29th. Mizuho upped their target price on shares of Evolus from $16.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, June 11th. Zacks Investment Research raised shares of Evolus from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a report on Tuesday, July 17th. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $27.00 target price on shares of Evolus in a report on Monday, August 6th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Evolus has a consensus rating of “Buy” and a consensus target price of $30.40.
Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Thursday, August 2nd. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.05). sell-side analysts forecast that Evolus will post -1.9 EPS for the current year.
In related news, Director Kristine Romine acquired 10,000 shares of the firm’s stock in a transaction on Wednesday, August 22nd. The shares were purchased at an average price of $19.83 per share, with a total value of $198,300.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Corp Alphaeon sold 1,000,000 shares of the stock in a transaction dated Monday, July 23rd. The stock was sold at an average price of $18.80, for a total transaction of $18,800,000.00. The disclosure for this sale can be found here.
Large investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new stake in Evolus during the 2nd quarter worth about $108,000. Tower Research Capital LLC TRC grew its holdings in Evolus by 761.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,555 shares of the company’s stock worth $183,000 after acquiring an additional 5,794 shares during the last quarter. Schwab Charles Investment Management Inc. bought a new stake in Evolus during the 2nd quarter worth about $258,000. Alpine Woods Capital Investors LLC bought a new stake in Evolus during the 2nd quarter worth about $280,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in Evolus during the 2nd quarter worth about $303,000. 13.20% of the stock is currently owned by hedge funds and other institutional investors.
Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.